TurboFil & Amneal Pharmaceuticals Join Forces to Fight Against Opioid-Related Deaths; Here’s What You Need To Know

TurboFil Packaging Machines LLC, a company specializing in the design and development of liquid filling and assembly machines, is joining forces with Bridgewater, NJ-based Amneal Pharmaceuticals. Together, they aim to develop an advanced automated assembly and vial filling machine tailored for unidose liquid nasal devices. TurboFil’s system will be used by Amneal in producing naloxone doses, the life-saving drug utilized to act against the opioid overdoses.

This collaboration follows the U.S. Food and Drug Administration’s (FDA) recent approval of the over-the-counter selling of naloxone hydrochloride nasal spray, USP, 4mg. This product, the general version of Narcan, is important for treating opioid overdose emergencies.TurboFil’s system comes with advanced inspection capabilities, making sure that each device can effectively perform its critical, time-sensitive role. The machine's precise and flexible design incorporates state-of-the-art technology, meeting or exceeding the stringent accuracy tolerances required. 

“Intranasal administration devices are among the fastest-growing forms of drug delivery, and we’re proud to work with Amneal in their mission to expand availability of a drug on the forefront of the urgent fight against opioid-related deaths,” added by Deborah Smook, VP of Marketing & Business Development for TurboFil Packaging Machines LLC. By combining classical mechanics with modern technology, TurboFil’s machine guarantees precision assembly of these crucial devices, supporting the urgent need for the reliable production of naloxone. 

Jiten Parikh, Senior Vice President Of Operations At Amneal Pharmaceuticals said that “We are excited to work with TurboFil on this project. Their advanced technology and expertise will help us advance our production capabilities and expand access to this crucial medication.”